EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyse

Cancer Trends in Inborn Errors of Immunity: A Systematic Review and Meta-Analysis

Saba Fekrvand, Hassan Abolhassani, Zahra Hamidi Esfahani, Najmeh Nameh Goshay Fard, Mahboube Amiri, Helia Salehi, Amir Almasi-Hashiani, Ali Saeedi-Boroujeni, Nazanin Fathi, Maryam Mohtashami, Azadehsadat Razavi, Arash Heidari und 7 weitere

Journal of Clinical Immunology · 2025-12 · 45 (1)

DOI: 10.1007/s10875-024-01810-w ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Journal of Clinical Immunology, online erschienen am 28.10.2024. Verfasst von Saba Fekrvand und 18 weiteren Autor:innen. Beteiligte Einrichtung: Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Ir…. Hauptthemen laut MEDLINE: Neoplasms. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 766 Literaturangaben. Gefördert von: Tehran University of Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Patients with inborn errors of immunity (IEI) are susceptible to developing cancer due to defects in the immune system. The prevalence of cancer is higher in IEI patients compared to the immunocompetent population and cancers are considered as an important and common cause of death in IEI patients. OBJECTIVES: To systematically review demographic, genetic and cancer-related data of IEI patients with a history of malignancy. Moreover, we performed a meta-analysis aiming to determine the frequency of cancer in patients with different types of IEI. METHODS: We conducted electronic searches on Embase, Web of Science, PubMed, and Scopus (until September 2023) introducing terms related to IEI and cancer. Studies with human subjects with confirmed IEI who had developed at least one malignancy during their lifetime were included. RESULTS: A total number of 4607 IEI patients with a cancer history were included in the present study. Common variable immunodeficiency (CVID) had the highest number of reported cases (1284 cases), mainly due to a higher relative proportion of patients with predominantly antibody deficiencies (PAD) and their increased life expectancy contributing to the higher detection and reporting of cancers among these patients. The most common malignancy was hematologic/blood cancers (3026 cases, mainly diffuse large B cell lymphoma). A total number of 1173 cases (55.6%) succumbed to cancer, with the highest rate of bone marrow failure (64.9%). Among the patients with monogenic defects in IEI-associated genes, the majority of cases had ATM deficiency (926 cases), but the highest cancer frequency rate belonged to NBS1 deficiency (50.5%). 1928 cases out of total 4607 eligible cases had detailed data to allow further statistical analysis that revealed BRCA2 deficiency had the earliest cancer development (~ 38 months), lowest cure frequency, and highest fatality rate (85%), while ATM deficiency had the lowest cure frequency and highest fatality rate (72%) among total cases reviewed with exclusion of Fanconi anemia. CONCLUSION: The overall reported cancer frequency in the cases reviewed with and without exclusion of Fanconi anemia was 11.1% (95% confidence interval: 9.8-12.5%) and 12.0% (95% confidence interval: 10.6-13.5%), respectively. Our study revealed that the incidence of cancer is significantly dependent on the molecular and pathway defects in IEI patients, and individualized early screening and appropriate treatment, might improve the prognosis of these patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsHumansPrevalence

Stichwörter der Autor:innen

DNA Repair DefectsHematologic CancersInborn Errors of ImmunityMalignancyPrimary Immunodeficiency Diseases

Autor:innen und Institutionen

  • Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.
  • Primary Immunodeficiency Diseases Network (PIDNet), Universal Scientific Education and Research Network (USERN), Tehran, Iran.
  • Division of Clinical Immunology, Department of Biosciences and Nutrition, Karolinska Institutet, Karolinska University Hospital, Stockholm, Huddinge, Sweden.
  • Thalassemia & Hemoglobinopathy Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
  • Department of Epidemiology, School of Health, Arak University of Medical Sciences, Arak, Iran.
  • Department of Basic Medical Sciences, Faculty of Medicine, Abadan University of Medical Sciences, Abadan, Iran.

Förderung

  • Tehran University of Medical Sciences

Zitieren

APA

Fekrvand, S., Abolhassani, H., Esfahani, Z. H., Fard, N. N. G., Amiri, M., Salehi, H., Almasi-Hashiani, A., Saeedi-Boroujeni, A., Fathi, N., Mohtashami, M., Razavi, A., Heidari, A., Azizi, G., Khanmohammadi, S., Ahangarzadeh, M., Saleki, K., Hassanpour, G., Rezaei, N., & Yazdani, R. (2025). Cancer Trends in Inborn Errors of Immunity: A Systematic Review and Meta-Analysis. Journal of Clinical Immunology, 45(1). https://doi.org/10.1007/s10875-024-01810-w

Vancouver

Fekrvand S, Abolhassani H, Esfahani ZH, Fard NNG, Amiri M, Salehi H, et al. Cancer Trends in Inborn Errors of Immunity: A Systematic Review and Meta-Analysis. Journal of Clinical Immunology. 2025;45(1). doi:10.1007/s10875-024-01810-w

BibTeX
@article{Fekrvand2025,
  author = {Fekrvand, Saba and Abolhassani, Hassan and Esfahani, Zahra Hamidi and Fard, Najmeh Nameh Goshay and Amiri, Mahboube and Salehi, Helia and Almasi-Hashiani, Amir and Saeedi-Boroujeni, Ali and Fathi, Nazanin and Mohtashami, Maryam and Razavi, Azadehsadat and Heidari, Arash and Azizi, Gholamreza and Khanmohammadi, Shaghayegh and Ahangarzadeh, Milad and Saleki, Kiarash and Hassanpour, Gholamreza and Rezaei, Nima and Yazdani, Reza},
  title = {Cancer Trends in Inborn Errors of Immunity: A Systematic Review and Meta-Analysis},
  journal = {Journal of Clinical Immunology},
  year = {2025},
  volume = {45},
  number = {1},
  doi = {10.1007/s10875-024-01810-w}
}
Kostenlos starten →